Showing results (141-150 of 237) with videos related to
Sort By:
Pageof 24
Annals of Hematology|June 5, 2026
What is the best path towards allogeneic transplantation in MDS and AML? A survey among German-spreaking centers for allogeneic hematopoietic stem cell transplantationStefan W Krause, Wolfgang Bethge, Gesine Bug, et al.Haematologica|October 19, 2010
Liposomal cytarabine is effective and tolerable in the treatment of central nervous system relapse of acute lymphoblastic leukemia and very aggressive lymphomaNicola Gökbuget, Christina-Maria Hartog, Renato Bassan, et al.Bone Marrow Transplantation|December 3, 2025
Posttransplant cyclophosphamide versus antithymocyte globulin in patients with cardiovascular comorbidity undergoing allogeneic hematopoietic cell transplantation for acute myeloid leukaemia in first complete remission from unrelated donors: a retrospective matched-pair analysis from the ALWP of the EBMTJan Vydra, Allain-Thibeault Ferhat, Nicolaus Kröger, et al.Blood Advances|April 12, 2024
Association of leukemic molecular profile with efficacy of inotuzumab ozogamicin in adults with relapsed/refractory ALLYaqi Zhao, A Douglas Laird, Kathryn G Roberts, et al.Blood|April 28, 2006
Alternating versus concurrent schedules of imatinib and chemotherapy as front-line therapy for Philadelphia-positive acute lymphoblastic leukemia (Ph+ ALL)Barbara Wassmann, Heike Pfeifer, Nicola Goekbuget, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 20, 2021
Comparison Between 5-Azacytidine Treatment and Allogeneic Stem-Cell Transplantation in Elderly Patients With Advanced MDS According to Donor Availability (VidazaAllo Study)Nicolaus Kröger, Katja Sockel, Christine Wolschke, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 26, 2023
Inotuzumab Ozogamicin as Induction Therapy for Patients Older Than 55 Years With Philadelphia Chromosome-Negative B-Precursor ALLMatthias Stelljes, Simon Raffel, Nael Alakel, et al.Bone Marrow Transplantation|May 5, 2023
Total body irradiation versus busulfan based intermediate intensity conditioning for stem cell transplantation in ALL patients >45 years-a registry-based study by the Acute Leukemia Working Party of the EBMTKlaus Hirschbühl, Myriam Labopin, Emmanuelle Polge, et al.Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|November 10, 2015
Allogeneic Stem Cell Transplantation Improves Survival in Patients with Acute Myeloid Leukemia Characterized by a High Allelic Ratio of Mutant FLT3-ITDAnthony D Ho, Johannes Schetelig, Tilmann Bochtler, et al.Bone Marrow Transplantation|December 24, 2025
The impact of DNMT3A mutation on survival of AML patients receiving allotransplant in first remission depends on the karyotype and co-occurring mutationsIman Abou Dalle, Jacques-Emmanuel Galimard, Xavier Poire, et al.Pageof 24